vs
Crane NXT, Co.（CXT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Crane NXT, Co.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$387.7M vs $207.3M），Crane NXT, Co.净利率更高（1.7% vs -62.0%，领先63.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 17.4%），Crane NXT, Co.自由现金流更多（$-24.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.3%）
Crane NXT是一家总部位于美国康涅狄格州斯坦福德的工业产品企业，由理查德·特勒·克莱恩于1855年创立。曾是美国头部卫浴配件制造商，1990年出售卫浴业务后，自1960年起逐步转型为多元化控股集团，目前核心业务涵盖航空航天与电子、工程材料、流体处理、控制设备四大板块，服务化工等多个行业领域。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CXT vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $387.7M | $207.3M |
| 净利润 | $6.4M | $-128.6M |
| 毛利率 | 40.2% | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 1.7% | -62.0% |
| 营收同比 | 17.4% | 25.9% |
| 净利润同比 | -70.5% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $387.7M | — | ||
| Q4 25 | $476.9M | $207.3M | ||
| Q3 25 | $445.1M | $159.9M | ||
| Q2 25 | $404.4M | $166.5M | ||
| Q1 25 | $330.3M | $139.3M | ||
| Q4 24 | $399.1M | $164.6M | ||
| Q3 24 | $403.5M | $139.5M | ||
| Q2 24 | $370.6M | $147.0M |
| Q1 26 | $6.4M | — | ||
| Q4 25 | $47.5M | $-128.6M | ||
| Q3 25 | $50.5M | $-180.4M | ||
| Q2 25 | $24.9M | $-115.0M | ||
| Q1 25 | $21.7M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $47.1M | $-133.5M | ||
| Q2 24 | $41.6M | $-131.6M |
| Q1 26 | 40.2% | — | ||
| Q4 25 | 42.4% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 41.7% | — | ||
| Q1 25 | 42.4% | — | ||
| Q4 24 | 45.2% | — | ||
| Q3 24 | 42.5% | — | ||
| Q2 24 | 43.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | -54.7% | ||
| Q3 25 | 18.4% | -106.9% | ||
| Q2 25 | 11.8% | -64.8% | ||
| Q1 25 | 11.3% | -102.6% | ||
| Q4 24 | 17.7% | -74.3% | ||
| Q3 24 | 18.6% | -94.6% | ||
| Q2 24 | 18.2% | -79.1% |
| Q1 26 | 1.7% | — | ||
| Q4 25 | 10.0% | -62.0% | ||
| Q3 25 | 11.3% | -112.8% | ||
| Q2 25 | 6.2% | -69.0% | ||
| Q1 25 | 6.6% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 11.7% | -95.7% | ||
| Q2 24 | 11.2% | -89.5% |
| Q1 26 | — | — | ||
| Q4 25 | $0.82 | $-1.28 | ||
| Q3 25 | $0.87 | $-1.81 | ||
| Q2 25 | $0.43 | $-1.17 | ||
| Q1 25 | $0.38 | $-1.57 | ||
| Q4 24 | $1.00 | $-1.34 | ||
| Q3 24 | $0.81 | $-1.40 | ||
| Q2 24 | $0.72 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $228.3M | $421.0M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $3.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.22× | — |
8季度趋势，按日历期对齐
| Q1 26 | $228.3M | — | ||
| Q4 25 | $233.8M | $421.0M | ||
| Q3 25 | $182.4M | $202.5M | ||
| Q2 25 | $152.5M | $176.3M | ||
| Q1 25 | $173.8M | $127.1M | ||
| Q4 24 | $165.8M | $174.0M | ||
| Q3 24 | $165.1M | $150.6M | ||
| Q2 24 | $175.5M | $480.7M |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $834.3M | — | ||
| Q2 25 | $861.8M | — | ||
| Q1 25 | $541.1M | — | ||
| Q4 24 | $540.6M | — | ||
| Q3 24 | $638.2M | — | ||
| Q2 24 | $638.9M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $989.8M | $432.4M |
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.1B | $1.5B | ||
| Q3 25 | $2.9B | $1.2B | ||
| Q2 25 | $2.9B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.6B |
| Q1 26 | 1.22× | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-24.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | -6.2% | -48.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $105.8M | $-99.8M | ||
| Q3 25 | $92.0M | $-91.4M | ||
| Q2 25 | $62.8M | $-108.3M | ||
| Q1 25 | $-19.1M | $-166.5M | ||
| Q4 24 | $81.1M | $-79.3M | ||
| Q3 24 | $66.7M | $-67.0M | ||
| Q2 24 | $56.8M | $-77.0M |
| Q1 26 | $-24.1M | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $78.7M | $-92.7M | ||
| Q2 25 | $55.8M | $-110.7M | ||
| Q1 25 | $-32.2M | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $53.5M | $-68.6M | ||
| Q2 24 | $47.9M | $-79.0M |
| Q1 26 | -6.2% | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | 17.7% | -58.0% | ||
| Q2 25 | 13.8% | -66.5% | ||
| Q1 25 | -9.7% | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | 13.3% | -49.2% | ||
| Q2 24 | 12.9% | -53.7% |
| Q1 26 | 2.6% | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | 3.0% | 0.8% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 4.0% | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 3.3% | 1.2% | ||
| Q2 24 | 2.4% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.23× | — | ||
| Q3 25 | 1.82× | — | ||
| Q2 25 | 2.52× | — | ||
| Q1 25 | -0.88× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.42× | — | ||
| Q2 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXT
| Detection and Traceability Technologies | $194.9M | 50% |
| Security and Authentication Technologies | $192.8M | 50% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
